What the record says
BPC-157 + TB-500: what each half of the blend rests on
BPC-157: the 2025 systematic review kept 36 studies out of 544 screened, 35 of them preclinical, and found no clinical safety data.
HSS J 2025;21:485–495 ↗TB-500 (thymosin beta-4): the one controlled human trial randomised 72 dry-eye subjects for 28 days and missed both primary endpoints, with secondary measures improving instead.
Clin Ophthalmol 2015;9:877–884 ↗A 2026 Sports Medicine review of approved and unapproved peptides places BPC-157 and thymosin beta-4 in the unapproved group and states that rigorous human safety data for that group are scarce.
Sports Med 2026;56:1921–1935 ↗
Compared with BPC-157 5 mg: The KLOW blend is the same compounds as the single vials sold next to it — plus GHK-Cu and KPV — in one vial instead of several. Nothing in the cited literature tests the combination; each component is documented on its own page.
Read the BPC-157 vs TB-500 comparison




